These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19424184)

  • 1. Profit-hungry pharma sees some biotechs as ripe for the picking.
    Willyard C
    Nat Med; 2009 May; 15(5):466. PubMed ID: 19424184
    [No Abstract]   [Full Text] [Related]  

  • 2. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 3. Western biotechs ponder follow-on possibilities.
    Waltz E
    Nat Biotechnol; 2008 Sep; 26(9):962-3. PubMed ID: 18779793
    [No Abstract]   [Full Text] [Related]  

  • 4. Fresh from the biologic pipeline-2009.
    Sheridan C
    Nat Biotechnol; 2010 Apr; 28(4):307-10. PubMed ID: 20379168
    [No Abstract]   [Full Text] [Related]  

  • 5. Value creation and sharing among universities, biotechnology and pharma.
    Edwards MG; Murray F; Yu R
    Nat Biotechnol; 2003 Jun; 21(6):618-24. PubMed ID: 12776145
    [No Abstract]   [Full Text] [Related]  

  • 6. Brand biologics grab 12 years' exclusivity, for now.
    Osborne R
    Nat Biotechnol; 2009 Aug; 27(8):677-8. PubMed ID: 19668153
    [No Abstract]   [Full Text] [Related]  

  • 7. Biotechs hedge against big pharma givebacks.
    Dorey E
    Nat Biotechnol; 1999 May; 17(5):416-7. PubMed ID: 10331784
    [No Abstract]   [Full Text] [Related]  

  • 8. Biotech jostles with pharma for slice of HIV market.
    Katsnelson A
    Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
    [No Abstract]   [Full Text] [Related]  

  • 9. Bills target biosimilar drugs.
    Wadman M
    Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
    [No Abstract]   [Full Text] [Related]  

  • 10. Any diamonds in the diagnostic coal?
    Jacobs T
    Nat Biotechnol; 2006 Aug; 24(8):930. PubMed ID: 16900133
    [No Abstract]   [Full Text] [Related]  

  • 11. Biotechs go generic: the same but different.
    Ledford H
    Nature; 2007 Sep; 449(7160):274-6. PubMed ID: 17882194
    [No Abstract]   [Full Text] [Related]  

  • 12. Russian fund steps up investments in innovative biotechs.
    Katsnelson A
    Nat Biotechnol; 2012 Jan; 30(1):9-11. PubMed ID: 22231078
    [No Abstract]   [Full Text] [Related]  

  • 13. Mammalian cell culture capacity for biopharmaceutical manufacturing.
    Ecker DM; Ransohoff TC
    Adv Biochem Eng Biotechnol; 2014; 139():185-225. PubMed ID: 23748352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Big pharmas seek biotechs that deliver.
    Dove A
    Nat Biotechnol; 2001 May; 19(5):398. PubMed ID: 11328985
    [No Abstract]   [Full Text] [Related]  

  • 15. Merck moves into biotech.
    Kling J
    Nat Biotechnol; 2006 Jul; 24(7):730. PubMed ID: 16841041
    [No Abstract]   [Full Text] [Related]  

  • 16. Gearing up for follow-on biologics.
    Hughes B
    Nat Rev Drug Discov; 2009 Mar; 8(3):181. PubMed ID: 19247295
    [No Abstract]   [Full Text] [Related]  

  • 17. How the street sees biotech.
    Lashinsky A
    Fortune; 2003 Jun; 147(11):86. PubMed ID: 12800576
    [No Abstract]   [Full Text] [Related]  

  • 18. 'Biosimilar' drugs poised to penetrate market.
    Ledford H
    Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
    [No Abstract]   [Full Text] [Related]  

  • 19. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
    Scattereggia J
    IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deal watch: Biopharma deal-making in 2015: changing the pharma landscape.
    Micklus A; Muntner S
    Nat Rev Drug Discov; 2016 Feb; 15(2):78-9. PubMed ID: 26837586
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.